/
CLDI
$0.16-$0.00 (-1.23%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.1M
19M shares
52-week range
$0.12 – $19.20
0% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XASE
CS
Borrow rate
13.69%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-587.84
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $449.0K | $45.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $94.0K | $274.0K | $1.3M | $0 | $1.7M |
| Gross profit | $0 | $355.0K | −$229.0K | −$1.3M | $0 | −$1.7M |
| Gross margin | — | 79.1% | -508.9% | — | — | — |
| R&D | $3.2M | $4.7M | $7.3M | $13.0M | $8.9M | $9.7M |
| Operating income | −$6.8M | −$10.5M | −$23.1M | −$29.0M | −$21.8M | −$20.2M |
| EBITDA | −$6.7M | −$9.4M | −$25.0M | −$24.2M | −$19.7M | −$18.2M |
| Net income | −$7.9M | −$10.9M | −$25.4M | −$29.2M | −$22.1M | −$19.9M |
| Net margin | — | -2435.0% | -56504.4% | — | — | — |
| EPS (diluted) | -2.64 | 14.16 | -358.80 | -207.61 | -35.70 | -5.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-5.52 | $-5.52–$-5.52 | 1 |
| 2027 | $0 | $-4.80 | $-4.80–$-4.80 | 1 |
| 2028 | $7M | $-4.68 | $-4.68–$-4.68 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.58
Price
$0.16
Implied upside
+258%
Peer comparison
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
www.calidibio.com- Employees
- 29
- IPO / List date
- Sep 13, 2023
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CLDI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CLDI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-05 | 1-for-12reverse |
| 2024-07-15 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded CLDI yet.
